Generally tend to agree with your analysis here. I did my Base/Covid split at the EBITDA line as the depreciation charge doesn't seem to be influenced that much by the Base/Covid revenue mix. Using some pretty soft assumptions for H2 a $1.0B EBIT figure for the full year seems reasonable. However, do your own research and form your own views.
Ann: Half Yearly Report and Accounts, page-6
Add SHL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$25.72 |
Change
-0.110(0.43%) |
Mkt cap ! $12.33B | |||
| Open | High | Low | Value | Volume |
| $26.04 | $26.07 | $25.60 | $8.438M | 326.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1625 | $25.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $25.73 | 954 | 18 |
View Market Depth
| Last trade - 12.50pm 11/07/2024 (20 minute delay) ? |
| SHL (ASX) Chart |